Skip to main content
. 2022 Nov 6;42(12):1314–1330. doi: 10.1002/cac2.12385

FIGURE 5.

FIGURE 5

Quality of life analysis in ORIENT‐3. (A) Patients in the sintilimab arm reported better QLQ‐C30 Global Health Status scores from baseline to Cycle 15 than those in the docetaxel arm. (B) Patients in the sintilimab arm reported better EQ‐5D Visual Analog Scale from baseline to cycle 15 than those in the docetaxel arm. (C) Patients in the sintilimab arm had improvement in EORTC QLQ‐C30 fatigue, pain, dyspnea and appetite loss than those in the docetaxel arm. (D) Patients in the sintilimab arm showed improvement in EORTC QLQ‐LC13 dyspnea, coughing, hemoptysis, alopecia, pain in the arm or shoulder and pain in other parts than those in the docetaxel arm.

Abbreviations: EORTC, European Organization for Research and Treatment of Cancer; QLQ‐C30, quality of life questionnaire score 30; GHS, Global Health Status; EQ‐5D, EuroQol five‐dimensional questionnaire; VAS, visual analog scale; QLQ‐LC13, Quality of life questionnaire‐lung cancer 13.